Zentalis Pharmaceuticals, Inc. Equity Securities, FV-NI, Gain (Loss)
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $152.00K.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $3.47M, a 38.76% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for fiscal 2025 was $1.24M, a 76.30% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for fiscal 2024 was $5.23M.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for fiscal 2023 was $0.00.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, gain (loss) for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $152.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $152.00K derived: sum of 2 quarters · filed 2026-05-12 | $3.62M derived: sum of 3 quarters · filed 2026-05-12 | $8.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.62M derived: sum of 2 quarters · filed 2026-03-26 | $8.26M derived: sum of 3 quarters · filed 2026-08-06 | $1.24M 10-K · filed 2026-03-26 |
| 2025-09-30 | $3.47M 10-Q · filed 2025-11-10 | $8.11M derived: sum of 2 quarters · filed 2026-08-06 | $1.09M 10-Q · filed 2025-11-10 | -$1.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.64M 10-Q · filed 2026-08-06 | -$2.38M 10-Q · filed 2026-08-06 | -$5.08M derived: sum of 3 quarters · filed 2026-08-06 | $591.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$7.02M 10-Q · filed 2026-05-12 | -$9.71M derived: sum of 2 quarters · filed 2026-05-12 | -$4.05M derived: sum of 3 quarters · filed 2026-05-12 | -$32.97M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.97M derived: sum of 2 quarters · filed 2026-03-26 | -$25.94M derived: sum of 3 quarters · filed 2026-03-26 | $5.23M 10-K · filed 2026-03-26 |
| 2024-09-30 | $5.67M 10-Q · filed 2025-11-10 | -$23.25M derived: sum of 2 quarters · filed 2025-11-10 | $7.92M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$28.92M 10-Q · filed 2025-08-06 | $2.25M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $31.17M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |